Should I have a DNA fragmentation test?

What is sperm DNA fragmentation?

The DNA in a sperm cell is extraordinarily tightly packaged. During sperm production, most histones are replaced with protamines so the paternal genome can be compressed and protected inside the sperm head.

DNA strand breaks can arise during abnormal sperm development or through oxidative stress during maturation and storage.

SDF tests attempt to quantify this damage. Common assays include:

• SCSA (sperm chromatin structure assay);
• TUNEL;
• SCD or “halo” testing;
• Comet assays.

They do not measure exactly the same biological property, and thresholds are not directly interchangeable.²

Is high DNA fragmentation associated with infertility?

Yes, at a population level there are associations.

Higher SDF is seen more often in infertile populations and can correlate with factors such as age, smoking, varicocele and abnormal conventional semen parameters.²

Some meta-analyses have also associated elevated SDF with pregnancy or miscarriage outcomes.

That explains why the test has attracted serious scientific interest and why some international guidance in previous years gave it a possible role in selected cases.³

The question, however, is not whether DNA damage matters biologically. It clearly can.

The question is: does measuring SDF in an individual man reliably change what we should do, and improve the chance of a live birth?

How good is SDF at predicting whether a pregnancy will happen?

A major 2026 critical appraisal drew on a systematic review and meta-analysis of 52 studies involving 19,930 participants.²

For predicting pregnancy, sensitivity was consistently low:

• Comet: 0.547
• SCD: 0.486
• SCSA: 0.360
• TUNEL: 0.369

Specificity was only modest, generally around 0.65–0.76.^{2, 4}

In plain English, many couples who do not conceive will not be identified by the test, while an abnormal result does not reliably tell you that conception or live birth will fail.

The authors concluded that SDF does not meet the performance requirements expected of a population screening test, a stand-alone diagnostic test or a robust prognostic test.²

Does that mean sperm DNA damage is irrelevant?

No.

This is an important distinction.

A biomarker can be biologically relevant without being accurate enough to guide routine individual decisions.

Blood pressure is both biologically meaningful and clinically actionable because there is strong evidence that measuring and treating it changes outcomes. With SDF, there is still uncertainty about:

• which assay should be used;
• which threshold matters;
• which patient subgroup benefits most;
• whether treating an elevated result improves live birth;
• whether different interventions should be chosen because of the result.

That gap between interesting biology and proven clinical utility is the heart of the controversy.

What does NICE 2026 actually say?

NICE now states:

• Do not carry out testing for sperm DNA integrity (fragmentation).¹
• Do not offer surgical sperm retrieval solely as a way to improve outcomes in non-azoospermic men with reduced sperm DNA integrity.⁵

The evidence review explains the reasoning: evidence did not show clear enough benefits from treating elevated fragmentation to justify routine testing, and SDF assays can add cost and delay in time-sensitive fertility pathways.⁶

This is stronger wording than some older international recommendations.

Why might I have heard that international guidelines recommend it?

Because guidance has evolved and remains inconsistent.

The 2021 European Association of Urology guideline described SDF as an emerging biomarker and recognised possible clinical use in selected scenarios.³

Some andrology experts continue to advocate targeted testing—for example after recurrent pregnancy loss, repeated ART failure or clinical varicocele—rather than routine use.⁷

So the controversy is real. It should not be hidden from patients.

As of 2026, however, NICE is explicitly against routine SDF testing in the UK fertility pathway.¹

If my SDF result is high, what can be done?

This is where the evidence becomes especially important.

Potential strategies proposed in the literature include:

• smoking cessation;
• weight optimisation;
• avoiding excessive heat;
• shorter ejaculatory abstinence;
• treating a suitable clinical varicocele;
• antioxidant supplementation;
• laboratory sperm-selection methods;
• in selected research/clinical contexts, testicular sperm for ICSI.

Some of these can reduce SDF values in studies. But lowering a fragmentation percentage is not automatically evidence of more live births.

NICE’s 2026 evidence review concluded that the available evidence did not show sufficiently clear benefit from treating SDF to justify testing as a routine pathway.⁶

What about using ICSI because SDF is high?

A 2026 analysis examining whether SDF could identify couples who benefit from ICSI rather than conventional IVF found no SDF quartile in which ICSI improved cumulative live birth. Even in the highest DFI group, cumulative live birth was 45.2% with ICSI versus 49.1% with conventional IVF; the adjusted difference was not significant.⁸

ICSI did reduce total fertilisation failure in the highest-DFA quartile in that study, but this did not translate into improved live birth.⁸

That is precisely why treatment decisions should not be made from one biomarker without considering outcomes that matter to patients.

What if I have recurrent miscarriage or unexplained infertility?

These are the situations in which the desire for an additional male test is most understandable.

SDF may still be discussed by specialists in selected, complex cases, particularly where standard investigations have been unrevealing. But the patient should understand that this is not a universally endorsed diagnostic test and that a result may not lead to a treatment proven to improve live birth.

Before paying for an SDF test, useful questions are:

1. What specific clinical question will this test answer for us?
2. Which assay is being used and why?
3. What threshold defines “high” in this laboratory?
4. If it is high, exactly what would you change?
5. Is that intervention proven to improve live birth, or mainly the DFI number?
6. Would we make the same treatment decision without the test?

If the final answer to question six is yes, the test may not be adding much.

How strong is the evidence?

There are many observational studies and meta-analyses linking SDF to reproductive outcomes. The weakness is clinical discrimination and intervention evidence.

The 2026 appraisal of 52 studies and nearly 20,000 participants found low sensitivity and only modest specificity.² NICE’s current recommendation against testing reflects uncertainty about whether a result leads to an effective change in treatment.^{1, 6}

Therefore the evidence is strong enough to say DNA integrity matters biologically, but not strong enough for NICE to support routine clinical testing.

What does the UK regulator say?

Worth knowing before you pay for this privately.

The Human Fertilisation and Embryology Authority lists sperm DNA damage among fertility treatment add-ons and gives it no rating at all — not green, not red, not even the grey used for insufficient evidence. For calibration, nothing currently on the HFEA's add-ons list holds a green rating, and several widely sold extras are rated red.

NICE reached the same place by a different route: the committee found the link between elevated fragmentation and subfertility is not established, the assays are expensive and slow, there is no consensus on which test or threshold counts as elevated, and it recommends against offering supplements, antioxidants or medical treatments to improve sperm DNA integrity.

Set that beside how the test is marketed and the gap is obvious.

Bottom line

Sperm DNA fragmentation is a real biological phenomenon. But the current evidence does not support treating the test as a definitive measure of sperm quality or a universal explanation for infertility.

The most important 2026 update is straightforward:

NICE recommends that sperm DNA integrity/fragmentation testing should not be carried out routinely.¹

There may still be selected complex cases where an andrologist discusses it, particularly in the context of research or unresolved recurrent reproductive failure. But the test should be presented as an uncertain adjunct, not as a hidden diagnosis that conventional medicine has missed.

If you are considering paying for SDF testing, the key question is not “Can it measure DNA damage?”

It can.

The key question is: “Will knowing this result change our treatment in a way proven to improve our chance of a live birth?”

I order this test rarely and I will explain why before you pay for it. The thresholds are not standardised between laboratories, the treatments it leads to are weaker still, and a high result too often becomes a reason to buy something rather than a reason to do something. Where it genuinely changes a decision, I will say so.